StockTipsArenaBeta

BUY Shilpa Medicare Limited — Sumeet Bagadia, Choice Broking

BUYShilpa Medicare Limited
Shilpa Medicare share price target & all analyst calls

bySumeet Bagadia, Choice BrokingHorizon: NA (inferred Swing (≤2wk))3 Sept 2026via LiveMint Buy-or-Sell (topic)

Entry₹929Stated
Target₹1,010
Total upside +8.72% (call closed)
Stop loss₹874-5.92% risk
At expiry₹957.517 Sept 2026, 3:30 pm
Expired+3.07%
Follow Sumeet Bagadia for new calls(29% target hit, 407 closed calls)Get alertsWatch SHILPAMED for new buy/sell callsGet alertsSee 147 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 17 Sept 2026
2 supporting1 opposing
Supports the BUY call (2)

Shilpa Medicare gets final approval for 5-day chemotherapy anti-nausea injection

NewsCnbc-Tv18·11 Sept · 6d ago

(opens in new tab)

Shilpa Medicare's novel injectable OERIS (Ondansetron Extended-Release Injection, 100 mg/mL) has received final approval from the Subject Expert Committee (SEC) for marketing.

BSE · Company Update·11 Sept · 6d ago

(opens in new tab)
Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (1)

Shilpa Medicare Limited Initiates Recall of Pemrydi Rtu (Pemetrexed Injection) Due to Discolored Solution

NewsGoogle News·29 Aug · 3w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Shilpa Medicare

All analyst calls on Shilpa Medicare

More from Sumeet Bagadia, Choice Broking

Every call and its outcome